Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

Inclusion Criteria: * Subject must voluntarily sign the informed consent form before any study-related procedures, understand and communicate with the investigator smoothly during the trial, and understand and voluntarily strictly abide by the provisions of this clinical study protocol; * Age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form, male or female; * Body Mass Index (BMI) ≥ 18 and ≤ 39 kg/m2 at screening; * Fulfilled the 2006 Classification Criteria for Psoriatic Arthritis (CASPAR) and had symptoms of psoriatic arthritis for more than 6 months but less than 12 months of evolution at screening * Had active PsA before randomization (defined as ≥ 3/68 tender joint count and ≥ 3/66 swollen joint count); * Active plaque psoriasis (at least one plaque lesion) at screening, or a history of plaque psoriasis; * Failure to respond or stabilize on NSAIDs and/or csDMARDs (Inadequate Responders) * Female subjects of childbearing potential must have a negative pregnancy test during the screening period and prior to randomization. Exclusion Criteria: * History of Drug-induced psoriasis (including, but not limited to, psoriasis induced by beta-blockers, calcium channel inhibitors, or lithium); * Had other active inflammatory diseases or autoimmune diseases other than psoriatic arthritis, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, reactive arthritis, inflammatory bowel disease arthritis, etc.; * History of organ trans…